CI

At a glance

ClinicalIndex Comparison Record
N/ACompleted· 142 enrolled
Drug / intervention
iLux 2020 System +1 moredevice
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT03055832
NCT03055832N/ACompleted
CompareCT.gov

Randomized Comparison Between iLux™ and LipiFlow® in the Treatment of Meibomian Gland Dysfunction

Tear Film Innovations, Inc.·interventional·Posted Feb 16, 2017·Updated Apr 12, 2023

In Brief

A clinical study evaluating iLux 2020 System and LipiFlow Pulsation System for Meibomian Gland Dysfunction. Completed, enrolled 142 participants across 7 sites.

Detailed Summary

The purpose of this study was to compare changes in meibomian gland dysfunction (MGD), tear break-up time (TBT) and evaporative dry eye (EDE) symptoms after treatment with either the iLux® 2020 System or the LipiFlow® Thermal Pulsation System.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsMeibomian Gland Dysfunction
CountriesUnited States
Collaborators--

Timeline

N/ACompletedFinished
2017201820192020202120222023202420252026
First PostedFeb 16, 2017
Enrollment StartFeb 9, 2017
Primary CompletionJul 20, 2017
TodayJul 2, 2026
Enrollment to primary: 5 monthsPosted 9.4 years ago

Interventions

iLux 2020 Systemdevice

Medical device that applies localized heat and pressure therapy to the eyelid in order to express melted meibum from obstructed glands

LipiFlow Pulsation Systemdevice

Medical device that applies a combination of heat and pressure to the inner eyelid to remove gland obstructions and stagnant gland content